Compare COLB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COLB | TGTX |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.9B |
| IPO Year | 1996 | 2008 |
| Metric | COLB | TGTX |
|---|---|---|
| Price | $30.79 | $54.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $31.46 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 3.1M | 2.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 1.38 | 0.17 |
| Revenue | ★ $177,000,000.00 | $2,785,000.00 |
| Revenue This Year | $31.52 | $49.08 |
| Revenue Next Year | $2.90 | $26.69 |
| P/E Ratio | ★ $22.35 | $297.41 |
| Revenue Growth | ★ 18.94 | N/A |
| 52 Week Low | $23.83 | $26.76 |
| 52 Week High | $33.68 | $59.30 |
| Indicator | COLB | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 59.92 |
| Support Level | $30.78 | $51.22 |
| Resistance Level | $31.11 | $58.08 |
| Average True Range (ATR) | 0.59 | 2.10 |
| MACD | -0.11 | 0.39 |
| Stochastic Oscillator | 8.11 | 80.70 |
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.